|Trade names||Fraxiparin, Fraxiparine, Fraxodi, others|
|Other names||Nadroparin calcium|
|Drug class||Low molecular weight heparin (LMWH)|
|Main uses||Prevent and treat blood clots|
|Side effects||Bruising at the site of injection, bleeding, heparin induced thrombocytopenia, high potassium|
|Subcutaneous injection (except for haemodialysis)|
|AHFS/Drugs.com||International Drug Names|
|Bioavailability||89% (SC dose)|
|Elimination half-life||3.7 hours (SC dose)|
|Excretion||clearance 21.4mL/min (+/- 7)|
|Chemical and physical data|
|Molar mass||4300 g/mol|
Nadroparin, sold under the brand name Fraxiparin among others, is a medication used to prevent and treat blood clots, including deep vein thrombosis (DVT) and pulmonary embolism. It may be used following surgery, in people in hospital who are not moving, and as with hemodialysis. It is given by injection under the skin.
Common side effects include bruising at the site of injection and bleeding. Other side effects may include heparin induced thrombocytopenia and high potassium. In those with kidney problems, lower doses may be required. It is a low molecular weight heparin (LMWH) which works by attaching to plasma protein anti-thrombin III. It is made from unfractionated heparin.
Nadroparin was approved for medical use in Australia in 1995. It is on the World Health Organization's List of Essential Medicines as an alternative to enoxaparin. It is available in a number of European countries and Canada but not the United States.
Nadroparin was developed by Sanofi-Synthélabo.
- Davis, R; Faulds, D (April 1997). "Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders". Drugs & aging. 10 (4): 299–322. doi:10.2165/00002512-199710040-00006. PMID 9108990.
- "Fraxiparine" (PDF). TGA. Archived (PDF) from the original on 16 September 2023. Retrieved 13 September 2023.
- World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- "List of nationally authorised medicinal products" (PDF). EMA. Archived (PDF) from the original on 30 March 2023. Retrieved 9 September 2023.
- Frontera, Walter R.; Silver, Julie K. (26 September 2018). Essentials of Physical Medicine and Rehabilitation E-Book: Musculoskeletal Disorders, Pain, and Rehabilitation. Elsevier Health Sciences. p. 715. ISBN 978-0-323-54966-0. Archived from the original on 16 September 2023. Retrieved 13 September 2023.